FMP
NASDAQ
0.7 USD
-0.0587 (-8.39%)
Mr. Stephen F. Mahoney J.D., MBA
Healthcare
Biotechnology
https://www.magentatx.com
NASDAQ
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Ph...
0001690585
US55910K1088
55910K108
100 Technology Square
857 242 0170
US
67
Jun 21, 2018
0001690585
NASDAQ
Biotechnology
Healthcare
55910K108
US55910K1088
US
0.7
2.11
247.98k
42.44M
-
0.321-1.81
3.71
-
-
-
-
-0.61
-
https://www.magentatx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.